Search
Neuronetics Inc
STIMAdd to Watchlist
1.410USD
+0.060+4.44%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
98.11MMarket Cap
LossP/E TTM
More Details of Neuronetics Inc Company
Neuronetics, Inc. a vertically integrated, commercial stage, medical technology and healthcare company. The Company’s NeuroStar Advanced Therapy (NeuroStar Therapy) is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions. In addition to selling the NeuroStar Advanced Therapy System (NeuroStar System) and associated treatment sessions to customers, it operates Greenbrook treatment centers across the United States, offering NeuroStar Therapy for the treatment of major depressive disorder (MDD) and other mental health disorders. Spravato is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. MDD is a recurrent disease and follows a fluctuating course over an individual’s lifetime. The Company provides more than 7.1 million treatments to over 1,95,000 patients.
Neuronetics Inc Info
Ticker SymbolSTIM
Company nameNeuronetics Inc
IPO dateJun 28, 2018
CEOMr. Keith J. Sullivan
Number of employees716
Security typeOrdinary Share
Fiscal year-endJun 28
Address3222 Phoenixville Pike
CityMALVERN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code19355
Phone18776007555
Websitehttps://neurostar.com/neuronetics/
Ticker SymbolSTIM
IPO dateJun 28, 2018
CEOMr. Keith J. Sullivan
Company Executives of Neuronetics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Sasha Cucuz
Mr. Sasha Cucuz
Director
Director
2.06M
+1.46%
Mr. Steven Pfanstiel
Mr. Steven Pfanstiel
Chief Financial Officer, Executive Vice President, Treasurer
Chief Financial Officer, Executive Vice President, Treasurer
828.78K
+1.03%
Mr. Robert A. (Rob) Cascella
Mr. Robert A. (Rob) Cascella
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
625.02K
+5.80%
Mr. Glenn P. Muir
Mr. Glenn P. Muir
Independent Director
Independent Director
340.45K
+8.81%
Ms. Sheryl L. Conley
Ms. Sheryl L. Conley
Independent Director
Independent Director
190.35K
+15.76%
Ms. Megan Rosengarten
Ms. Megan Rosengarten
Independent Director
Independent Director
170.89K
+17.56%
Mr. Mark Klausner
Mr. Mark Klausner
Managing Partner
Managing Partner
--
--
Mr. W. Andrew Macan
Mr. W. Andrew Macan
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
--
--
Dr. Avinash N. Amin, M.D.
Dr. Avinash N. Amin, M.D.
Director
Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Sasha Cucuz
Mr. Sasha Cucuz
Director
Director
2.06M
+1.46%
Mr. Steven Pfanstiel
Mr. Steven Pfanstiel
Chief Financial Officer, Executive Vice President, Treasurer
Chief Financial Officer, Executive Vice President, Treasurer
828.78K
+1.03%
Mr. Robert A. (Rob) Cascella
Mr. Robert A. (Rob) Cascella
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
625.02K
+5.80%
Mr. Glenn P. Muir
Mr. Glenn P. Muir
Independent Director
Independent Director
340.45K
+8.81%
Ms. Sheryl L. Conley
Ms. Sheryl L. Conley
Independent Director
Independent Director
190.35K
+15.76%
Ms. Megan Rosengarten
Ms. Megan Rosengarten
Independent Director
Independent Director
170.89K
+17.56%
FAQs
Who are the top five shareholders of Neuronetics Inc?
The top five shareholders of Neuronetics Inc are: Mr. Sasha Cucuz
How many institutions hold shares of Neuronetics Inc (STIM)?
As of 2026Q1, 236 institutions hold shares of Neuronetics Inc, with a combined market value of approximately 47.87M, accounting for 68.80% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -7188276.00.
What is the biggest source of revenue for Neuronetics Inc?
In 2026Q1, the Clinic revenue business generated the highest revenue for Neuronetics Inc, amounting to 86.98M and accounting for 58.31% of total revenue.